Trial Profile
A phase I trial of LY573636 administered as a 24-hour continuous infusion on day 1 of a 28-day cycle in patients with refractory solid tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Feb 2006
Price :
$35
*
At a glance
- Drugs Tasisulam (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 03 Feb 2006 New trial record.